Filtered By:
Condition: Dermatitis
This page shows you your search results in order of date. This is page number 10.
Order by Relevance | Date
Total 8248 results found since Jan 2013.
Targeting type 2 immune activation beyond atopic dermatitis
Ann Allergy Asthma Immunol. 2023 Jul 12:S1081-1206(23)00490-8. doi: 10.1016/j.anai.2023.06.028. Online ahead of print.NO ABSTRACTPMID:37442541 | DOI:10.1016/j.anai.2023.06.028
Source: Annals of Allergy, Asthma and Immunology - July 13, 2023 Category: Allergy & Immunology Authors: Donald Ym Leung Paola Facheris Karen Veverka Ferda Cevikbas Emma Guttman-Yassky Source Type: research
Oral difelikefalin reduces moderate to severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis
Pruritus is the most common and burdensome symptom of atopic dermatitis (AD). Pruritus-targeted treatments in AD are lacking, particularly for patients with milder skin disease.
Source: Journal of Allergy and Clinical Immunology - July 13, 2023 Category: Allergy & Immunology Authors: Emma Guttman-Yassky, Paola Facheris, Joel Correa Da Rosa, Camille Rothenberg-Lausell, Ester del Duca, Eden David, Yeriel Estrada, Ying Liu, Swaroop Bose, Mashkura Chowdhury, Catherine Munera, Joana Goncalves, Kristine Nograles, Brian S. Kim, Mark Lebwohl Source Type: research
Oral difelikefalin reduces moderate-to-severe pruritus and expression of pruritic and inflammatory biomarkers in subjects with atopic dermatitis
Pruritus is the most common and burdensome symptom of atopic dermatitis (AD). Pruritus-targeted treatments in AD are lacking, particularly for patients with milder skin disease.
Source: Journal of Allergy and Clinical Immunology - July 13, 2023 Category: Allergy & Immunology Authors: Emma Guttman-Yassky, Paola Facheris, Joel Correa Da Rosa, Camille Rothenberg-Lausell, Ester del Duca, Eden David, Yeriel Estrada, Ying Liu, Swaroop Bose, Mashkura Chowdhury, Catherine Munera, Joana Goncalves, Kristine Nograles, Brian S. Kim, Mark Lebwohl Source Type: research
Difelikefalin suppresses itch and reduces scratching independent of inflammation in a murine model of atopic dermatitis
Treatments specifically targeting pruritus are lacking. The current results demonstrate that difelikefalin, a kappa opioid receptor agonist, reduces itch in a mouse model of atopic dermatitis via a neuromodulatory mechanism.
Source: Journal of Allergy and Clinical Immunology - July 13, 2023 Category: Allergy & Immunology Authors: Masato Tamari, Lydia Zamidar, Aaron M. Ver Heul, Kristine Nograles, Joana Goncalves, Emma Guttman-Yassky, Mark Lebwohl, Brian S. Kim Source Type: research
Targeting type 2 immune activation beyond atopic dermatitis
Abbreviations/Acronyms:
Source: Annals of Allergy, Asthma and Immunology - July 11, 2023 Category: Allergy & Immunology Authors: Donald YM Leung, Paola Facheris, Karen Veverka, Ferda Cevikbas, Emma Guttman-Yassky Tags: Perspective Source Type: research
Prevalence of atopic dermatitis in the adolescent population of Catalonia (Spain)
CONCLUSIONS: This is the first Spanish study reporting the overall diagnosed prevalence for a large-scale adolescent cohort (12-17 years old) from Catalonia. It provides new and robust evidence of AD's prevalence and related characteristics in this region.PMID:37422786 | DOI:10.15586/aei.v51i4.893
Source: Allergologia et Immunopathologia - July 9, 2023 Category: Allergy & Immunology Authors: Toni Mora Irene S ánchez-Collado Joaquim Mullol Rosa Mu ñoz-Cano Paula Rib ó Antonio Valero Source Type: research
